12th
June
2008
Modified adenovirus boosts p53 to help fight cancer
Introgen Therapeutics, Inc. concluded phase III clinical trials for a new drug that may be able to replace methotrexate in treatment of head and neck cancers in certain patients. It shows fewer negative side effects than methotrexate, thus improving the quality of life for the patient in treatment. Life expectancy also increased for patients with a favorable p53 profile.
Cells become cancerous because p53 no longer functions. Restoring p53 works unlike any current cancer treatment because it treats the cancer genome.
posted in Medicine | 0 Comments